



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Hywel Dda  
University Health Board

Ein cyf/Our ref: AWMSG to Dec 2013 [4]  
Gofynnwch am/Please ask for: Sue Beach  
Rhif Ffôn /Telephone: 01554 783462  
Ffacs/Facsimile:  
E-bost/E-mail: [sue.beach@wales.nhs.uk](mailto:sue.beach@wales.nhs.uk)

Dr Carol Llewellyn-Jones  
Glangwili General Hospital  
Dolgwili Road, Carmarthen,  
Carmarthenshire, SA31 2AF  
Tel: 01267 235151

Dr Carol Llewellyn-Jones  
Ysbyty Cyffredinol Glangwili  
Heol Dolgwili, Caerfyrddin  
Sir Gaerfyrddin, SA31 2AF  
Rhif Ffôn: 01267 235151

DATE 7<sup>th</sup> Feb 2014

BY EMAIL Page 1 of 2

**TO: All prescribers  
County lead pharmacists  
Assistant Director of Nursing (Practice)  
Hywel Dda Health Board global email**

Dear Colleague

The appraisals listed below have been published by the All Wales Medicines Strategy Group (AWMSG). They have been assessed for local implementation and their place in therapy established as described.

**Please ensure that your teams are fully aware of this information.**

In accordance with the provisions of Welsh Ministerial Letter ML/009 /09 (see EH/ML/009/09: <http://www.wales.nhs.uk/documents/EH-ML-009-09.pdf>, 19.3.09), these drugs are being added to the Health Board's formulary, <http://hywelddahb.inform.wales.nhs.uk/>, and will be available for prescribing in accordance with the guidance.

Please ensure that the appropriate audit forms are completed for all initiations on these therapies in the next 12 months. You will find the audit forms on the Clinical Systems (NICE / TA AWMSG appraisal audits) pages of the Health Board's Intranet: <http://howis.wales.nhs.uk/sitesplus/862/page/43199>

Pharmacy has been notified of the guidance and you should be aware that prescriptions that fall outside the recommendations of AWMSG guidance will be discussed with prescribers before dispensing. Please note that failure to complete the appropriate audit form may result in a delay in dispensing.

**AWMSG 1813 1509 Nepafenac (Nevanac®)**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1509>

Added to the Formulary as an option but with a note that no use currently expected. Hospital Only.

**AWMSG 2813/188 Lisdexamfetamine dimesylate (Elvanse®)**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/188>

The position in treatment pathway for lisdexamfetamine is being determined by the relevant consultants.

**AWMSG 2513/549 Pazopanib (Votrient®) for metastatic relapsed soft tissue sarcoma,**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/549>

Specialist oncology and hospital use only.

**AWMSG 2713 1074 5-aminolaevulinic acid (Ameluz®)**

Pencadlys Bwrdd Iechyd Prifysgol Hywel Dda  
Llys Myrddin, Lôn Winch, Hwlfordd,  
Sir Benfro, SA61 1SB  
Rhif Ffôn: (01437) 771220  
Rhif Ffacs: (01437) 771222

Hywel Dda University Health Board Headquarters  
Merlins Court, Winch Lane, Haverfordwest,  
Pembrokeshire, SA61 1SB  
Tel Nr: (01437) 771220  
Fax Nr: (01437) 771222

Cadeirydd / Chairman  
**Mr Chris Martin**  
Prif Weithredwr / Chief Executive  
**Yr Athro/Professor Trevor Purt**

Bwrdd Iechyd Prifysgol Hywel Dda yw enw gweithredol Bwrdd Iechyd Lleol Prifysgol Hywel Dda  
Hywel Dda University Health Board is the operational name of Hywel Dda University Local Health Board

Mae Bwrdd Iechyd Prifysgol Hywel Dda yn amgylchedd di-fwg Hywel Dda University Health Board operates a smoke free environment

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1074>

Added to the Formulary as an option but with a note that no use currently expected as Photodynamic therapy for actinic keratosis is not undertaken in HDUHB. Hospital Only.

**AWMSG 2413 1446 Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®) for HIV**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1446>

Specialist and hospital use only.

**AWMSG 2913 1609 Raltegravir (Isentress®)**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1609>

1. 25 mg and 100 mg chewable tablets, in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in children aged 2–11 years: **specialist and hospital use only.**
2. 400 mg film-coated tablets, in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infection in adolescents and children from the age of 6 years and weighing ≥ 25kg: **specialist and hospital use only.**

**AWMSG 2613 926 Tegafur/gimeracil/oteracil (Teysono®) for gastric cancer**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/928>

Specialist oncology and hospital use only.

**AWMSG 3513 1437 Etanercept (Enbrel®) for paediatric and adolescent polyarthritis, psoriatic arthritis and enthesitis-related arthritis**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1437>

Specialist and hospital use only.

**AWMSG 3313 1975 Saxagliptin (Onglyza®)**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1975>

Adults: triple therapy for type II diabetes approved for use in primary & secondary care.

**AWMSG 3113 863 Lixisenatide (Lyxumia®)**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/863>

The position in treatment pathway for lixisenatide is being determined by the Diabetic Network consultants.

**AWMSG 3213 1683 Etravirine (Intelence®) for paediatric HIV**

<http://www.awmsg.org/awmsgonline/app/appraisalinfo/1683>

Specialist and hospital use only.

If you have any questions relating to the guidance or this process, please contact Sue Beach, Lead Clinical Development Pharmacist, on 01554 783084; email [sue.beach@wales.nhs.uk](mailto:sue.beach@wales.nhs.uk).

Dr Carol Llewellyn-Jones  
Consultant Physician  
Chairman, Medicines Management Group  
AMD Carmarthenshire